After pricing six million American Depositary Shares, (ADSs), at a $6.00 per ADS public offering price, today’s IPO of Belite Bio, Inc (BLTE), opened at $12.50

Benchmark Company, LLC will be the sole bookrunner for this offering.

Belite Bio is an innovative therapeutics company that develops novel therapies for eye diseases. It’s based in San Diego and focuses on treating untreatable conditions such as retinal degeneration.